Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]
In order to get FDA approval, drugs must first go through a clinical trial that demonstrates that they offer a better treatment result than the current standard of care. In some instances the better result can be a demonstration that the investigational drug provides an advantage which is only palliative (as Mitoxantrone does for advance [...]
Today, I spent most of the day listening to the CME (Medicare & Medicaid) hearing on Provenge. CME does not have to abide to the decisions of the advisory committee, so like we experienced with the FDA Advisory Committees we will have to wait and see what will eventually become the policy for reimbursement. I [...]
There has been a lot of controversy over the association between obesity and the eventual biochemical failure of men treated for prostate cancer. Research performed at the Cleveland Clinic, Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio attempted to determined whether there is an association between body mass index and biochemical failure [...]
Men who experience a reoccurrence post surgery will usually be referred for salvage radiation therapy. The goal of the radiation is to simply eliminate the stray cancer cells that might have remained in the prostate bed. The only way we currently have to monitor the outcomes from this radiation is to monitor PSA. Researchers at [...]